Detalhe da pesquisa
1.
Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial.
Eur Heart J
; 45(13): 1173-1176, 2024 Apr 01.
Artigo
Inglês
| MEDLINE | ID: mdl-38252107
2.
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).
Circulation
; 137(4): 338-350, 2018 01 23.
Artigo
Inglês
| MEDLINE | ID: mdl-29133605
3.
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.
Lancet
; 390(10106): 1962-1971, 2017 Oct 28.
Artigo
Inglês
| MEDLINE | ID: mdl-28859947
4.
Effectiveness of icosapent ethyl on first and total cardiovascular events in patients with metabolic syndrome, but without diabetes: REDUCE-IT MetSyn.
Eur Heart J Open
; 3(6): oead114, 2023 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-38035037
5.
Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial.
JAMA Cardiol
; 6(2): 139-147, 2021 02 01.
Artigo
Inglês
| MEDLINE | ID: mdl-32785614
6.
Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial.
J Am Coll Cardiol
; 73(23): 2961-2970, 2019 06 18.
Artigo
Inglês
| MEDLINE | ID: mdl-31196453
7.
Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.
JAMA Cardiol
; 2(12): 1385-1391, 2017 12 01.
Artigo
Inglês
| MEDLINE | ID: mdl-29117276
8.
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial.
Lancet Diabetes Endocrinol
; 5(12): 941-950, 2017 12.
Artigo
Inglês
| MEDLINE | ID: mdl-28927706